Abstract
Cancers of the urinary system are likely to be influenced by both the urinary and gut microbiotas. While commensal organisms do not densely colonize the urinary system, those present still play a significant role in health and disease. Like other organs, there is always a potential for malignancy to occur when microorganisms cause chronic inflammation. Additionally, the urinary system is commonly exposed to the waste products in the body, including those microbial metabolites from the gut which have entered the circulation. It is, therefore, possible that the microbiota of different sites contributes to the process of carcinogenesis through metabolic toxification and detoxification as well as immune interactions. The emerging clinical evidence also suggests a prominent role for microbiota in affecting the efficacy of cancer therapeutics, including chemotherapy and immunotherapy agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abbasian B et al (2019) Potential role of extracellular ATP released by bacteria in bladder infection and contractility. mSphere 4:1–14
Abdur-Rashid K, Nair S, Chanyi R, Chin J, Burton JP (2019) Xenobiotic metabolism of abiraterone acetate and glucocorticoids by the gut microbiota. J Urol 201:2019
Adebayo AS et al (2017) The microbiome in urogenital schistosomiasis and induced bladder pathologies. PLoS Negl Trop Dis 11:1–22
Bayne CE, Farah D, Herbst KW, Hsieh MH (2018) Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol 36:1181–1190
Beacham BL, Deatrick JAMY (2008) Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney Cancer working group. Bone 23:1–7
Buc E et al (2013) High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 8
Bučević Popović V et al (2018) The urinary microbiome associated with bladder cancer. Sci Rep 8:1–8
Burger M et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241
Casero RA, Stewart TM, Pegg AE (2019) Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer 18:681–695
Castellarin M et al (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22:299–306
Cho JH, Holley JL (2013) Squamous cell carcinoma of the bladder in a female associated with multiple bladder stones. BMC Res Notes 6(1)
Choueiri TK, Motzer RJ (2017) Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med 376:354–366
Chung SD, Tsai MC, Lin CC, Lin HC (2013) A case-control study on the association between bladder cancer and prior bladder calculus. BMC Cancer 13(1)
Chutipongtanate S, Sutthimethakorn S, Chiangjong W, Thongboonkerd V (2013) Bacteria can promote calcium oxalate crystal growth and aggregation. J Biol Inorg Chem 18:299–308
Colldén H et al (2017) The gut microbiota is a crucial regulator of local intestinal androgen metabolism in male mice. Endocr Rev 38:1182–1192
Com E et al (2003) Expression of antimicrobial Defensins in the male reproductive tract of rats, mice, and Humans1. Biol Reprod 68:95–104
Corthay A (2009) How do regulatory t cells work? Scand J Immunol 70:326–336
Cosseau C et al (2008) The commensal Streptococcus salivarius K12 downregulates the innate immune responses of Human epithelial cells and promotes. Infect Immun 76:4163–4175
De Nisco NJ et al (2019) Direct detection of tissue-resident bacteria and chronic inflammation in the bladder wall of postmenopausal women with recurrent urinary tract infection. J Mol Biol 431:4368–4379
Dellavalle CT et al (2013) Dietary intake of nitrate and nitrite and risk of renal cell carcinoma in the NIH-AARP diet and health study. Br J Cancer 108:205–212
Deng T et al (2017) Systematic review and cumulative analysis of the combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder Cancer. Sci Rep 7:1–10
Fan ST, Edgington TS (1989) Sufficiency of the CD8+ T cell lineage to mount an effective tumoricidal response to syngeneic tumor-bearing novel class I MHC antigens. J Immunol 143:4287–4291
Feldman B, Feldman D (2001) Androgen-independent prostate cancer androgen-independent prostate cancer. Nat Rev Cancer 1:34–45
Fernando MH, Jayarajah U, Herath KB, de Silva MVC, Goonewardena SAS (2017) Aggressive squamous cell carcinoma of the bladder associated with a history of large bladder stone – a case report. Clin Case Rep 5:1616–1619
Foxman B (2010) The epidemiology of urinary tract infection. Nat Rev Urol 7:653–660
Gopalakrishnan V et al (2018) Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97–103
Hahn AW et al (2018) Targeting Bacteroides in stool microbiome and response to treatment with first-line VEGF tyrosine kinase inhibitors in metastatic renal-cell carcinoma. Clin Genitourin Cancer 16:365–368
Heng DYC et al (2014) Consortium prognostic model: a population-based study. Lancet Oncol 14:141–148
Hinotsu S et al (2011) Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer. BJU Int 108:187–195
Ishida K, Hsieh MH (2018) Understanding urogenital schistosomiasis-related bladder cancer: an update. Front Med 5(1–7)
Jacouton E et al (2019) Elucidating the immune-related mechanisms by which probiotic strain Lactobacillus casei BL23 displays anti-tumoral properties. Front Microbiol 10:1–10
Kamat AM et al (2015) Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12:225–235
Kamat M, Hahn N, Efstathiou AJ (2016) Bladder cancer. Lancet 288:2796–2810
Kates M et al (2018) Intravesical BCG induces CD4+ T-cell expansion in an immune competent model of. Bladder Cancer 5:594–603
Kobayashi J (2018) Effect of diet and gut environment on the gastrointestinal formation of N-nitroso compounds: a review. Nitric Oxide – Biol Chem 73:66–73
Kostic AD et al (2014) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor immune microenvironment. Cell Host Microbe 14:207–215
Kurts C, Panzer U, Anders HJ, Rees AJ (2013) The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol 13:738–753
Lalani A-KA et al (2019) Effect of antibiotic use on outcomes with systemic therapies in metastatic renal cell carcinoma. Eur Urol Oncol 1:1–10
Loh YH et al (2011) N-nitroso compounds and cancer incidence: the European prospective investigation into cancer and nutrition (EPIC)-Norfolk study. Am J Clin Nutr 93:1053–1061
Louis P, Hold GL, Flint HJ (2014) The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12:661–672
Ma X et al (2019) The microbiome of prostate fluid is associated with prostate cancer. Front Microbiol 10:1–8
Magruder M et al (2019) Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun 10:1–9
Markowski MC et al (2019) The microbiome and genitourinary cancer: a collaborative review. Eur Urol 75:637–646
McMillan A, MacKlaim JM, Burton JP, Reid G (2013) Adhesion of lactobacillus iners AB-1 to human fibronectin: a key mediator for persistence in the vagina? Reprod Sci 20:791–796
Morand A, Cornu F, Dufour J-C, Tsimaratos M, Lagier J-C, Raoult D (2019) Human bacterial repertoire of the urinary tract: a potential paradigm shift. J Clin Microbiol 57:1–9
Mortara L et al (2018) Anti-cancer therapies employing IL-2 cytokine tumor targeting: contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy. Front Immunol 9:2905
Mostafa MH, Sheweita SA, O’Connor PJ (1999) Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 12:97–111
Motzer RJ et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290
Pal SK et al (2015) Stool Bacteriomic profiling in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor-tyrosine kinase inhibitors. Clin Cancer Res 21:5286–5293
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264
Park J et al (2015) Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol 8:80–93
Parker AS, Cerhan JR, Lynch CF, Leibovich BC, Cantor KP (2004) History of urinary tract infection and risk of renal cell carcinoma. Am J Epidemiol 159:42–48
Pathria P, Louis TL, Varner JA (2019) Targeting tumor-associated macrophages in cancer. Trends Immunol 40:310–327
Pearce MM et al (2015) The female urinary microbiome in urgency urinary incontinence. Am J Obstet Gynecol 213:347.e1–347.e11
Pederzoli F et al (2020) Sex-specific alterations in the urinary and tissue microbiome in therapy-naïve urothelial bladder cancer patients. Eur Urol Oncol 0:1–5
Pichler R et al (2016) Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-guérin therapy in bladder cancer. Oncotarget 7:39916–39930
Plaza-d J, Ruiz-ojeda FJ, Vilchez-padial LM, Gil A (2017) Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients 9:555
Porter CM, Shrestha E, Peiffer LB, Sfanos KS (2018) The microbiome in prostate inflammation and prostate cancer. Prostate Cancer Prostatic Dis 21:345–354
Poutahidis T et al (2014) Probiotic microbes sustain youthful serum testosterone levels and testicular size in aging mice. PLoS One 9:e84877
Qian Y, Wang X, Li Y, Cao Y, Chen X (2016) Extracellular ATP a new player in cancer metabolism: NSCLC cells internalize ATP in vitro and in vivo using multiple endocytic mechanisms. Metabolism 14:1087–1097
Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res 47:1762–1766
Ridlon JM et al (2013) Clostridium scindens: a human gut microbe with a high potential to convert glucocorticoids into androgens. 54:2437–2449
Riquelme E et al (2019) Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell 178:795–806.e12
Round J, Mazmanian S (2014) The gut microbiome shapes intestinal immune responses during health and disease. Nat Rev Immunol 9:25
Routy B et al (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91–97
Schwaderer AL, Wolfe AJ (2017) The association between bacteria and urinary stones. Ann Transl Med 5:3–8
Scott RP, Quaggin SE (2015) The cell biology of renal filtration. J Cell Biol 209:199–210
Sfanos KS et al (2018) Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis 21:539–548
Shrestha E et al (2018) Profiling the urinary microbiome in men with positive versus negative biopsies for prostate Cancer. J Urol 199:161–171
Sivick KE et al (2018) Magnitude of therapeutic STING activation determines CD8 + T cell-mediated anti-tumor immunity. Cell Rep 25:3074–3085.e5
Suez J et al (2018) Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174:1406–1423.e16
Takahashi S et al (2000) Mutation induction by mechanical irritation caused by uracil-induced urolithiasis in big blue® rats. Mutat Res - Fundam Mol Mech Mutagen 447:275–280
Tofalo R, Cocchi S, Suzzi G (2019) Polyamines and gut microbiota. Front Nutr 6:1–5
Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012
Tsoi TH et al (2016) Urinary polyamines: a pilot study on their roles as prostate cancer detection biomarkers. PLoS One 11:1–13
Turnbaugh PJ et al (2007) The human microbiome project. Nature 449:804–810
Vervaet BA, D’Haese PC, Verhulst A (2017) Environmental toxin-induced acute kidney injury. Clin Kidney J 10:747–758
Wang Y et al (2018) Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 24:1804–1808
Whiteside SA, Razvi H, Dave S, Reid G, Burton JP (2015) The microbiome of the urinary tract – a role beyond infection. Nat Rev Urol 12:81–90
Woenckhaus J, Fenic I (2008) Proliferative inflammatory atrophy: a background lesion of prostate cancer? Andrologia 40:134–137
Wolfe AJ et al (2012) Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol 50:1376–1383
Wroblewski LE, Peek RM, Wilson KT (2010) Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 23:713–739
Xu W et al (2014) Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am J Clin Exp Urol 2:57–61
Yoon SH et al (2009) Selective addition of CXCR3+CCR4-CD4+ Th1 cells enhances generation of cytotoxic T cells by dendritic cells in vitro. Exp Mol Med 41:161–170
Zhong X, Koenig SSK, Fu L, Ma Z, Zhou X (2013) Temporal dynamics of the human vaginal microbiota. Sci Transl Med 4:132
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The American Physiological Society
About this chapter
Cite this chapter
Krishnamoorthy, M., Maleki Vareki, S., Burton, J.P. (2021). The Microbiome and Urologic Cancers. In: Sun, J. (eds) Inflammation, Infection, and Microbiome in Cancers. Physiology in Health and Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-67951-4_8
Download citation
DOI: https://doi.org/10.1007/978-3-030-67951-4_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-67950-7
Online ISBN: 978-3-030-67951-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)